Eight months after filing for IPO, the maker of China's Ebola vaccine joins HKEX with $161M raise
The Hong Kong stock exchange is welcoming its first pre-revenue vaccine maker on board.
Tianjin-based CanSino scored $160.5 million in an IPO by selling 57.2 million shares at $2.8, or HK$22, the top of the range. Around 40% of the capital came from local investors and the rest went to international community, both of which oversubscribed. The public debut donned a valuation of $611.6 million, according to BioCentury.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.